New LaunchJun 15, 2026, 08:02 AM
Grifols Launches FESILTY Fibrinogen Concentrate in U.S.
AI Summary
Grifols announced the U.S. launch of FESILTY, a new fibrinogen concentrate, now available for treating acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency (CFD). Approved by the U.S. FDA in December, FESILTY expands Grifols' bleeding management portfolio by offering a highly purified product that enables rapid and predictable restoration of fibrinogen levels. This new treatment option provides healthcare professionals with a safe, effective, and reliable solution for a rare inherited condition.
Key Highlights
- Grifols launched FESILTY, a new fibrinogen concentrate, in the U.S.
- FESILTY is approved by the U.S. FDA for acute bleeding in pediatric and adult patients with congenital fibrinogen deficiency.
- The product offers rapid and predictable restoration of fibrinogen levels.
- It can be stored at room temperature and reconstitutes in approximately three minutes.
- FESILTY enhances Grifols' bleeding management portfolio and expands its plasma-derived medicines.
Price Impact
More from GRFS